{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T15:21:54Z","timestamp":1693927314448},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Am 30.06.2019 erfolgte die Ver\u00f6ffentlichung der S3-Leitlinie \u201eAktinische Keratose und Plattenepithelkarzinom der Haut\u201c. Zeitlich nachfolgend erschienen Publikationen, \u00dcbersichtsarbeiten und Metaanalysen mit neuen Fragestellungen zur Vergleichbarkeit von Studiendaten und zur Heterogenit\u00e4t der Auswertungen, die unter anderem durch divergente Messparameter wie auch unzureichende Ber\u00fccksichtigung von Vorbehandlungen und kombinierten Behandlungen bedingt sind. Im Kontext der Kritik und mit Blick auf notwendige Entwicklungen und Forschung wurde diese pr\u00e4gnante \u00dcbersicht verfasst. Thematische Abschnitte zur Epidemiologie, Pathogenese, Pr\u00e4vention, Klinik und Therapie wie auch BK (Berufskrankheit)\u00a05103 wurden erarbeitet. Die Therapie, untergliedert in lokal destruktive und topische arzneimittelgest\u00fctzte Verfahren, basiert auf den Leitlinienempfehlungen, die als Zitate gekennzeichnet und mit dem zugeh\u00f6rigen Evidenzlevel versehen sind. F\u00fcr die Umsetzung im Alltag werden Kerndaten, Nebenwirkungen und Besonderheiten der Therapeutika genannt. Die aktuellen Entwicklungen und Fragestellungen zu aktinischen Keratosen werden deutlich.<\/jats:p>","DOI":"10.1007\/s00105-020-04619-x","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T07:02:50Z","timestamp":1590735770000},"page":"463-475","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Aktinische Keratosen"],"prefix":"10.1007","volume":"71","author":[{"given":"D.","family":"Nashan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"H\u00fcning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. V.","family":"Heppt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Brehmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Berking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"4619_CR1","unstructured":"Leitlinienprogramm Onkologie (2019) S3-Leitlinie Aktinische Keratose und Plattenepithelkarzinom der Haut. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/aktinische-keratosen-und-plattenepithelkarzinom-der-haut\/. Zugegriffen: 26. Febr. 2020 (AWMF Registernummer:032\/0220L)"},{"key":"4619_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/1203475417708166","author":"P Fleming","year":"2017","unstructured":"Fleming\u00a0P, Zhou\u00a0S, Bobotsis\u00a0R, Lynde\u00a0C (2017) Comparison of the treatment guidelines for actinic keratosis: A critical appraisal and review. J\u00a0Cutan Med Surg. https:\/\/doi.org\/10.1177\/1203475417708166","journal-title":"J Cutan Med Surg"},{"key":"4619_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2017.10.008","author":"V Lai","year":"2018","unstructured":"Lai\u00a0V, Cranwell\u00a0W, Sinclair\u00a0R (2018) Epidemiology of skin cancer in the mature patient. Clin Dermatol. https:\/\/doi.org\/10.1016\/j.clindermatol.2017.10.008","journal-title":"Clin Dermatol"},{"key":"4619_CR4","doi-asserted-by":"publisher","DOI":"10.25646\/5977","volume-title":"Krebs in Deutschland f\u00fcr 2013 \/ 2014","author":"Robert Koch-Institut","year":"2017","unstructured":"Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.\u202fV. (2017) Krebs in Deutschland f\u00fcr 2013 \/ 2014, 11.\u00a0Aufl. https:\/\/doi.org\/10.25646\/5977","edition":"11"},{"key":"4619_CR5","doi-asserted-by":"publisher","DOI":"10.1159\/000491820","author":"PJ Dziunycz","year":"2018","unstructured":"Dziunycz\u00a0PJ, Schuller\u00a0E, Hofbauer\u00a0GFL (2018) Prevalence of actinic keratosis in patients attending general practitioners in Switzerland. Dermatology. https:\/\/doi.org\/10.1159\/000491820","journal-title":"Dermatology"},{"key":"4619_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14002","author":"M Krensel","year":"2019","unstructured":"Krensel\u00a0M, Petersen\u00a0J, Mohr\u00a0P, Weishaupt\u00a0C, Augustin\u00a0J, Sch\u00e4fer\u00a0I (2019) Estimating prevalence and incidence of skin cancer in Germany. J\u00a0Dtsch Dermatol Ges. https:\/\/doi.org\/10.1111\/ddg.14002","journal-title":"J Dtsch Dermatol Ges"},{"key":"4619_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/phpp.12213","author":"D Haluza","year":"2016","unstructured":"Haluza\u00a0D, Simic\u00a0S, H\u00f6ltge\u00a0J, Cervinka\u00a0R, Moshammer\u00a0H (2016) Gender aspects of recreational sun-protective behavior: Results of a\u00a0representative, population-based survey among Austrian residents. Photodermatol Photoimmunol Photomed. https:\/\/doi.org\/10.1111\/phpp.12213","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"4619_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2016.05.009","author":"S Mokni","year":"2017","unstructured":"Mokni\u00a0S, Fetoui Ghariani\u00a0N, Aounallah\u00a0A et\u00a0al (2017) Complications dermatologiques de l\u2019hydroxyur\u00e9e au long cours. Therapie. https:\/\/doi.org\/10.1016\/j.therap.2016.05.009","journal-title":"Therapie"},{"key":"4619_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15547","author":"R Aoki","year":"2019","unstructured":"Aoki\u00a0R, Clanner-Engelshofen\u00a0BM, Charnowski\u00a0S, Ruzicka\u00a0T, Reinholz\u00a0M (2019) Distribution of high-risk \u03b1\u2011genus human papillomavirus genotypes impacts cutaneous neoplasms. J\u00a0Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.15547","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4619_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3678-6","author":"N Buttmann-Schweiger","year":"2017","unstructured":"Buttmann-Schweiger\u00a0N, Deler\u00e9\u00a0Y, Klug\u00a0SJ, Kraywinkel\u00a0K (2017) Cancer incidence in Germany attributable to human papillomavirus in 2013. BMC Cancer. https:\/\/doi.org\/10.1186\/s12885-017-3678-6","journal-title":"BMC Cancer"},{"key":"4619_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14131","author":"L Zhang","year":"2018","unstructured":"Zhang\u00a0L, Qin\u00a0H, Wu\u00a0Z, Chen\u00a0W, Zhang\u00a0G (2018) Pathogenic genes related to the progression of actinic keratoses to cutaneous squamous cell carcinoma. Int J Dermatol. https:\/\/doi.org\/10.1111\/ijd.14131","journal-title":"Int J Dermatol"},{"key":"4619_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07860.x","author":"J R\u00f6wert-Huber","year":"2007","unstructured":"R\u00f6wert-Huber\u00a0J, Patel\u00a0MJ, Forschner\u00a0T et al (2007) Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07860.x","journal-title":"Br J Dermatol"},{"key":"4619_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12848","author":"MT Fern\u00e1ndez-Figueras","year":"2015","unstructured":"Fern\u00e1ndez-Figueras\u00a0MT, Carrato\u00a0C, S\u00e1enz\u00a0X et al (2015) Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J\u00a0Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.12848","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4619_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14512","author":"L Schmitz","year":"2018","unstructured":"Schmitz\u00a0L, Gambichler\u00a0T, Gupta\u00a0G et\u00a0al (2018) Actinic keratoses show variable histological basal growth patterns\u2014a\u00a0proposed classification adjustment. J\u00a0Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.14512","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4619_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16536","author":"L Schmitz","year":"2019","unstructured":"Schmitz\u00a0L, Gambichler\u00a0T, Kost\u00a0C et\u00a0al (2019) Cutaneous squamous cell carcinomas are associated with basal proliferating actinic keratoses. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.16536","journal-title":"Br J Dermatol"},{"key":"4619_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.13658_g","author":"L Schmitz","year":"2018","unstructured":"Schmitz\u00a0L, St\u00fccker\u00a0M, Gambichler\u00a0T, Stockfleth\u00a0E, Dirschka\u00a0T (2018) Die histologische intral\u00e4sionale Heterogenit\u00e4t aktinischer Keratosen als Zeichen von Feldkanzerisierung. J\u00a0Dtsch Dermatol Ges. https:\/\/doi.org\/10.1111\/ddg.13658_g","journal-title":"J Dtsch Dermatol Ges"},{"key":"4619_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4212","author":"KA Reynolds","year":"2019","unstructured":"Reynolds\u00a0KA, Schlessinger\u00a0DI, Vasic\u00a0J et\u00a0al (2019) Core outcome set for actinic keratosis clinical trials. JAMA Dermatol. https:\/\/doi.org\/10.1001\/jamadermatol.2019.4212","journal-title":"JAMA Dermatol"},{"key":"4619_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.3894","author":"DB Buller","year":"2015","unstructured":"Buller\u00a0DB, Berwick\u00a0M, Lantz\u00a0K, Buller\u00a0MK, Shane\u00a0J, Kane\u00a0I (2015) Evaluation of immediate and 12-week effects of a\u00a0smartphone sun-safety mobile application: a randomized clinical trial. JAMA Dermatol. https:\/\/doi.org\/10.1001\/jamadermatol.2014.3894","journal-title":"JAMA Dermatol"},{"key":"4619_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.02.029","author":"H Ou-Yang","year":"2012","unstructured":"Ou-Yang\u00a0H, Stanfield\u00a0J, Cole\u00a0C, Appa\u00a0Y, Rigel\u00a0D (2012) High-SPF sunscreens (SPF \u2265 70) may provide ultraviolet protection above minimal recommended levels by adequately compensating for lower sunscreen user application amounts. J\u00a0Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2012.02.029","journal-title":"J Am Acad Dermatol"},{"key":"4619_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10298.x","author":"M Lod\u00e9n","year":"2011","unstructured":"Lod\u00e9n\u00a0M, Beitner\u00a0H, Gonzalez\u00a0H et\u00a0al (2011) Sunscreen use: controversies, challenges and regulatory aspects. Br J Dermatol. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10298.x","journal-title":"Br J Dermatol"},{"key":"4619_CR21","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20131803","author":"M Ianhez","year":"2013","unstructured":"Ianhez\u00a0M, Fleury\u00a0LFF Jr, Miot\u00a0HA, Bagatin\u00a0E (2013) Retinoids for prevention and treatment of actinic keratosis. An Bras Dermatol. https:\/\/doi.org\/10.1590\/abd1806-4841.20131803","journal-title":"An Bras Dermatol"},{"key":"4619_CR22","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2017.3025","author":"F Drage","year":"2017","unstructured":"Drage\u00a0F, Ciccarese\u00a0G, Cogorno\u00a0L, Calvi\u00a0C, Marsano\u00a0LA, Parodi\u00a0A (2017) Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: a case-control study. Eur J Dermatol. https:\/\/doi.org\/10.1684\/ejd.2017.3025","journal-title":"Eur J Dermatol"},{"key":"4619_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14267","author":"T Dirschka","year":"2017","unstructured":"Dirschka\u00a0T, Pellacani\u00a0G, Micali\u00a0G et\u00a0al (2017) A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index. J\u00a0Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.14267","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4619_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17148","author":"MV Heppt","year":"2019","unstructured":"Heppt\u00a0MV, Steeb\u00a0T, Niesert\u00a0AC et\u00a0al (2019) Local interventions for actinic keratosis in organ transplant recipients: a\u00a0systematic review. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.17148","journal-title":"Br J Dermatol"},{"key":"4619_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096829","author":"S Vegter","year":"2014","unstructured":"Vegter\u00a0S, Tolley\u00a0K (2014) A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0096829","journal-title":"PLoS One"},{"key":"4619_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2009.04045.x","author":"DA Askew","year":"2009","unstructured":"Askew\u00a0DA, Mickan\u00a0SM, Soyer\u00a0HP, Wilkinson\u00a0D (2009) Effectiveness of 5\u2011fluorouracil treatment for actinic keratosis\u2014A systematic review of randomized controlled trials. Int J Dermatol. https:\/\/doi.org\/10.1111\/j.1365-4632.2009.04045.x","journal-title":"Int J Dermatol"},{"key":"4619_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.cd004415.pub2","author":"AK Gupta","year":"2012","unstructured":"Gupta\u00a0AK, Paquet\u00a0M, Villanueva\u00a0E, Brintnell\u00a0W (2012) Interventions for actinic keratoses. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.cd004415.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"4619_CR28","first-page":"255","volume":"94","author":"WD Hoover","year":"2014","unstructured":"Hoover\u00a0WD, Jorizzo\u00a0JL, Clark\u00a0AR, Feldman\u00a0SR, Holbrook\u00a0J, Huang\u00a0KE (2014) Efficacy of cryosurgery and 5\u2011fluorouracil cream 0.5\u202f% combination therapy for the treatment of actinic keratosis. Cutis 94(5):255\u2013259","journal-title":"Cutis"},{"key":"4619_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17435","author":"MV Heppt","year":"2019","unstructured":"Heppt\u00a0MV, Steeb\u00a0T, Ruzicka\u00a0T, Berking\u00a0C (2019) Cryosurgery combined with topical interventions for actinic keratosis: a\u00a0systematic review and meta-analysis. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.17435","journal-title":"Br J Dermatol"},{"key":"4619_CR30","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000000366","author":"JJ Speiser","year":"2015","unstructured":"Speiser\u00a0JJ, Garib\u00a0G, Novice\u00a0K, Peterson\u00a0A, Hutchens\u00a0KA (2015) Actinic keratosis, transected: what lies beneath? Am J Dermatopathol. https:\/\/doi.org\/10.1097\/DAD.0000000000000366","journal-title":"Am J Dermatopathol"},{"key":"4619_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15998","author":"T Steeb","year":"2019","unstructured":"Steeb\u00a0T, Wessely\u00a0A, Leiter\u00a0U, French\u00a0LE, Berking\u00a0C, Heppt\u00a0MV (2019) The more the better? An appraisal of combination therapies for actinic keratosis. J\u00a0Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.15998","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4619_CR32","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2167","author":"E Stockfleth","year":"2016","unstructured":"Stockfleth\u00a0E, Sibbring\u00a0GC, Alarcon\u00a0I (2016) New topical treatment options for actinic keratosis: A systematic review. Acta Derm Venereol. https:\/\/doi.org\/10.2340\/00015555-2167","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"4619_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s13555-016-0161-2","volume":"7","author":"E Stockfleth","year":"2017","unstructured":"Stockfleth\u00a0E, von Kiedrowski\u00a0R, Dominicus\u00a0R et al (2017) Efficacy and safety of 5\u2011fluorouracil 0.5\u202f%\/salicylic acid 10% in the field-directed treatment of actinic keratosis: a phase III, randomized, double-blind, vehicle-controlled trial. Dermatol Ther (Heidelb) 7(1):81\u201396. https:\/\/doi.org\/10.1007\/s13555-016-0161-2","journal-title":"Dermatol Ther (Heidelb)"},{"key":"4619_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12685","author":"R-M Szeimies","year":"2015","unstructured":"Szeimies\u00a0R\u2011M, Dirschka\u00a0T, Prechtl\u00a0A, Melzer\u00a0A (2015) Efficacy of low-dose 5\u2011fluorouracil\/ salicylic acid in actinic keratoses in relation to treatment duration [Wirksamkeit von niedrig-dosiertem 5\u2011fluorouracil\/salizyls\u00e4ure in abh\u00e4ngigkeit von der behandlungsdauer bei aktinischen keratosen]. J\u00a0Dtsch Dermatol Ges. https:\/\/doi.org\/10.1111\/ddg.12685","journal-title":"J Dtsch Dermatol Ges"},{"key":"4619_CR35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08271.x","author":"N Krawtchenko","year":"2007","unstructured":"Krawtchenko\u00a0N, Roewert-Huber\u00a0J, Ulrich\u00a0M, Mann\u00a0I, Sterry\u00a0W, Stockfleth\u00a0E (2007) A randomised study of topical 5\u202f% imiquimod vs. topical 5\u2011fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1\u2011year follow-up. Br J Dermatol. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08271.x","journal-title":"Br J Dermatol"},{"issue":"11","key":"4619_CR36","first-page":"1241","volume":"14","author":"EA Tanghetti","year":"2015","unstructured":"Tanghetti\u00a0EA, Hamann\u00a0C, Tanghetti\u00a0M (2015) A controlled comparison study of topical fluourouracil 5% cream pre-treatment of aminolevulinic acid\/photodynamic therapy for actinic keratosis. J\u00a0Drugs Dermatol 14(11):1241\u20131244","journal-title":"J Drugs Dermatol"},{"key":"4619_CR37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811850","author":"MHE Jansen","year":"2019","unstructured":"Jansen\u00a0MHE, Kessels\u00a0JPHM, Nelemans\u00a0PJ et\u00a0al (2019) Randomized trial of four treatment approaches for actinic keratosis. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1811850","journal-title":"N Engl J Med"},{"key":"4619_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18884","author":"MHE Jansen","year":"2020","unstructured":"Jansen\u00a0MHE, Kessels\u00a0JPHM, Merks\u00a0I et al (2020) A trial-based cost-effectiveness analysis of topical 5\u2011fluorouracil vs imiquimod vs ingenol mebutate vs methylaminolevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.18884","journal-title":"Br J Dermatol"},{"key":"4619_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700264","author":"G Hadley","year":"2006","unstructured":"Hadley\u00a0G, Derry\u00a0S, Moore\u00a0RA (2006) Imiquimod for actinic keratosis: systematic review and meta-analysis. J\u00a0Invest Dermatol. https:\/\/doi.org\/10.1038\/sj.jid.5700264","journal-title":"J Invest Dermatol"},{"key":"4619_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15868","author":"H Gollnick","year":"2020","unstructured":"Gollnick\u00a0H, Dirschka\u00a0T, Ostendorf\u00a0R, Kerl\u00a0H, Kunstfeld\u00a0R (2020) Long-term clinical outcomes of imiquimod 5% cream vs. diclofenac 3% gel for actinic keratosis on the face or scalp: a\u00a0pooled analysis of two randomized controlled trials. J\u00a0Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.15868","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4619_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.07.004","author":"N Swanson","year":"2010","unstructured":"Swanson\u00a0N, Abramovits\u00a0W, Berman\u00a0B, Kulp\u00a0J, Rigel\u00a0DS, Levy\u00a0S (2010) Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 2\u2011week cycles. J\u00a0Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2009.07.004","journal-title":"J Am Acad Dermatol"},{"key":"4619_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.06.020","author":"CW Hanke","year":"2010","unstructured":"Hanke\u00a0CW, Beer\u00a0KR, Stockfleth\u00a0E, Wu\u00a0J, Rosen\u00a0T, Levy\u00a0S (2010) Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3\u2011week cycles. J\u00a0Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2009.06.020","journal-title":"J Am Acad Dermatol"},{"key":"4619_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12782","author":"K Peris","year":"2015","unstructured":"Peris\u00a0K, Stockfleth\u00a0E, Gupta\u00a0G et\u00a0al (2015) Efficacy of imiquimod 3.75\u202f% from Lmax according to the number of actinic keratosis lesions. J\u00a0Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.12782","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4619_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15459","author":"MV Heppt","year":"2019","unstructured":"Heppt\u00a0MV, Steeb\u00a0T, Leiter\u00a0U, Berking\u00a0C (2019) Efficacy of photodynamic therapy combined with topical interventions for the treatment of actinic keratosis: a\u00a0meta-analysis. J\u00a0Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.15459","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4619_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.05.031","author":"D Pariser","year":"2008","unstructured":"Pariser\u00a0D, Loss\u00a0R, Jarratt\u00a0M et al (2008) Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: a randomized, double-blind, placebo-controlled study. J\u00a0Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2008.05.031","journal-title":"J Am Acad Dermatol"},{"key":"4619_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14498","author":"U Reinhold","year":"2016","unstructured":"Reinhold\u00a0U, Dirschka\u00a0T, Ostendorf\u00a0R et al (2016) A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz\u00ae) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoL. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.14498","journal-title":"Br J Dermatol"},{"key":"4619_CR47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09873.x","author":"RM Szeimies","year":"2010","unstructured":"Szeimies\u00a0RM, Radny\u00a0P, Sebastian\u00a0M et al (2010) Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a\u00a0prospective, randomized, double-blind, placebo-controlled phase III study. Br J Dermatol. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09873.x","journal-title":"Br J Dermatol"},{"key":"4619_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04386.x","author":"SR Wiegell","year":"2012","unstructured":"Wiegell\u00a0SR, Wulf\u00a0HC, Szeimies\u00a0RM et\u00a0al (2012) Daylight photodynamic therapy for actinic keratosis: An international consensus: International Society for Photodynamic Therapy in Dermatology. J\u00a0Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04386.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4619_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10833.x","author":"SR Wiegell","year":"2012","unstructured":"Wiegell\u00a0SR, Fabricius\u00a0S, Gniadecka\u00a0M et al (2012) Daylight-mediated photodynamic therapy of moderate to thick actinic keratoses of the face and scalp: a randomized multicentre study. Br J Dermatol. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.10833.x","journal-title":"Br J Dermatol"},{"key":"4619_CR50","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.9939","author":"M Tampa","year":"2019","unstructured":"Tampa\u00a0M, Sarbu\u00a0MI, Matei\u00a0C et al (2019) Photodynamic therapy: a hot topic in dermato-oncology (review). Oncol Lett. https:\/\/doi.org\/10.3892\/ol.2019.9939","journal-title":"Oncol Lett"},{"key":"4619_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2017.07.002","author":"JM Ang","year":"2017","unstructured":"Ang\u00a0JM, Riaz\u00a0IB, Kamal\u00a0MU, Paragh\u00a0G, Zeitouni\u00a0NC (2017) Photodynamic therapy and pain: a systematic review. Photodiagnosis Photodyn Ther. https:\/\/doi.org\/10.1016\/j.pdpdt.2017.07.002","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"4619_CR52","doi-asserted-by":"publisher","DOI":"10.23736\/S0392-0488.18.06011-X","author":"RM Szeimies","year":"2018","unstructured":"Szeimies\u00a0RM (2018) Pain perception during photodynamic therapy: Why is daylight PDT with methyl aminolevulinate almost pain-free? A review on the underlying mechanisms, clinical reflections and resulting opportunities. G\u00a0Ital Dermatol Venereol. https:\/\/doi.org\/10.23736\/S0392-0488.18.06011-X","journal-title":"G Ital Dermatol Venereol"},{"issue":"2","key":"4619_CR53","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/jdv.15185","volume":"33","author":"T Dirschka","year":"2019","unstructured":"Dirschka\u00a0T, Ekanayake-Bohlig\u00a0S, Dominicus\u00a0R et al (2019) A randomized, intraindividual, non-inferiority, Phase III study comparing daylight photodynamic therapy with BF-200 ALA gel and MAL cream for the treatment of actinic keratosis. J\u00a0Eur Acad Dermatol Venereol 33(2):288\u2013297. https:\/\/doi.org\/10.1111\/jdv.15185","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4619_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15422","author":"S Karrer","year":"2019","unstructured":"Karrer\u00a0S, Aschoff\u00a0RAG, Dominicus\u00a0R et al (2019) Methyl aminolevulinate daylight photodynamic therapy applied at home for non-hyperkeratotic actinic keratosis of the face or scalp: an open, interventional study conducted in Germany. J\u00a0Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.15422","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4619_CR55","series-title":"Information BK-F\u00e4lle BK-Nr. 5103","first-page":"1","volume-title":"Technische Information zur Ermittlung in Berufskrankheiten(BK-)f\u00e4llen vor dem Hintergrund der neuen Berufskrankheit mit der BK-Nr. 5103 \u201ePlattenepithelkarzinome oder multiple aktinische Keratosen der Haut durch nat\u00fcrliche UV-Strahlung\u201c","author":"M Wittlich","year":"2018","unstructured":"Wittlich\u00a0M (2018) Technische Information zur Ermittlung in Berufskrankheiten(BK-)f\u00e4llen vor dem Hintergrund der neuen Berufskrankheit mit der BK-Nr. 5103 \u201ePlattenepithelkarzinome oder multiple aktinische Keratosen der Haut durch nat\u00fcrliche UV-Strahlung\u201c. Information BK-F\u00e4lle BK-Nr. 5103, S 1\u201318"},{"key":"4619_CR56","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-018-4171-0","author":"M Rocholl","year":"2018","unstructured":"Rocholl\u00a0M, Ludewig\u00a0M, Skudlik\u00a0C, Wilke\u00a0A (2018) Occupational skin cancer: Prevention and recommendations for UV protection as part of the treatment approved by the public statutory employers\u2019 liability insurance. Hautarzt. https:\/\/doi.org\/10.1007\/s00105-018-4171-0","journal-title":"Hautarzt"},{"issue":"1","key":"4619_CR57","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/14728214.2020.1730810","volume":"25","author":"P Cramer","year":"2020","unstructured":"Cramer\u00a0P, Stockfleth\u00a0E (2020) Actinic keratosis: where do we stand and where is the future going to take us? Expert Opin Emerg Drugs 25(1):49\u201358. https:\/\/doi.org\/10.1080\/14728214.2020.1730810","journal-title":"Expert Opin Emerg Drugs"},{"key":"4619_CR58","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1254328","author":"T Dirschka","year":"2017","unstructured":"Dirschka\u00a0T, Gupta\u00a0G, Micali\u00a0G et al (2017) Real-world approach to actinic keratosis management: practical treatment algorithm for office-based dermatology. J\u00a0Dermatolog Treat. https:\/\/doi.org\/10.1080\/09546634.2016.1254328","journal-title":"J Dermatolog Treat"},{"key":"4619_CR59","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14652","author":"I Figueras Nart","year":"2018","unstructured":"Figueras Nart\u00a0I, Cerio\u00a0R, Dirschka\u00a0T et\u00a0al (2018) Defining the actinic keratosis field: a\u00a0literature review and discussion. J\u00a0Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.14652","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4619_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3696-6","author":"MV Heppt","year":"2019","unstructured":"Heppt\u00a0MV, Steeb\u00a0T, Schmitz\u00a0L et\u00a0al (2019) Harmonisation of Outcome Parameters and Evaluation (HOPE) for actinic keratosis: protocol for the development of a\u00a0core outcome set. Trials. https:\/\/doi.org\/10.1186\/s13063-019-3696-6","journal-title":"Trials"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-020-04619-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-020-04619-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-020-04619-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T23:30:57Z","timestamp":1622244657000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-020-04619-x"}},"subtitle":["Aktuelle Leitlinie und praxisbezogene Empfehlungen"],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["4619"],"URL":"https:\/\/doi.org\/10.1007\/s00105-020-04619-x","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]},"assertion":[{"value":"29 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>D.\u00a0Nashan<\/b>: A.\u00a0Finanzielle Interessen: Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: MSD, BMS, Novartis, Roche, Almirall, Mylan, Sanofi. \u2013 Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00c4.: MSD, BMS, Novartis, Roche, Almirall, Mylan, Sanofi. \u2013 B.\u00a0Nichtfinanzielle Interessen: Chef\u00e4rztin der Hautklinik Dortmund gGmbH | Mitgliedschaften: DDG, ADF, ADO, EADO, DKG, DGP, S\u00fcdwestdeutsche Dermatologen, \u00c4rztlicher Verein Dortmund, Hautkrebs Netzwerk Deutschland (Beirat), DGG Vorstand (kooptiertes Mitglied), Ethikkommission der \u00c4rztekammer der Westf\u00e4lischen Wilhelms-Universit\u00e4t M\u00fcnster. <b>S.\u00a0H\u00fcning<\/b>: A.\u00a0Finanzielle Interessen: Reisekosten\u00fcbernahme und\/oder Teilnahme an Advisory Boards: Novartis, MSD, Roche, Sun Pharma, Pierre Fabre. \u2013 B.\u00a0Nichtfinanzielle Interessen: Funktionsober\u00e4rztin, Hautklinik Klinikum Dortmund gGmbH | Mitgliedschaften: DDG, ADH und ADO. <b>M.\u00a0Heppt<\/b>: A.\u00a0Finanzielle Interessen: Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Galderma, Biofrontera. \u2013 Bezahlter Berater\/interner Schulungsreferent\/Gehaltsempf\u00e4nger o.\u202f\u00c4.: Almirall Hermal. \u2013 B.\u00a0Nichtfinanzielle Interessen: Oberarzt an der Hautklinik, Universit\u00e4tsklinikum Erlangen. <b>A.C.\u00a0Brehmer<\/b>: A.\u00a0Finanzielle Interessen: A.C.\u00a0Brehmer gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellte Assistenz\u00e4rztin. <b>C.\u00a0Berking<\/b>: A.\u00a0Finanzielle Interessen: Finanzielle Unterst\u00fctzung eines Diagnostik-Forschungsprojekts von der Firma Leo Pharma (an Drittmittelkonto Uniklinikum M\u00fcnchen). \u2013 Honorar als Referentin: Leo Pharma, Almirall-Hermal | Kostenerstattung f\u00fcr aktive Teilnahme (Vortrag) am PDT-Kongress: Galderma. \u2013 Mitglied Advisory Board: Almirall-Hermal, Biofrontera, Leo Pharma, Sun Pharma, Galderma. \u2013 B.\u00a0Nichtfinanzielle Interessen: Chef\u00e4rztin, Hautklinik, Universit\u00e4tsklinikum Erlangen (seit 10\/19) | Ober\u00e4rztin, Dermatologie, Klinikum der Universit\u00e4t M\u00fcnchen (bis 09\/2019) | Mitglied und Vorstandsmitglied der ADO (der DKG und DDG) sowie Nationale Versorgungskonferenz Hautkrebs | Mitgliedschaften: Deutsche Dermatologische Gesellschaft, UV-Schutzb\u00fcndnis | Koordinatorin der S3-Leitlinie \u201eAktinische Keratose und Plattenepithelkarzinom der Haut\u201c.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}